← back to search

Adam C. ElNaggar

Dartmouth College · US
Area of research
Reproductive Medicine · Cancer Research
Research interest
Research interests include Medicine, Internal medicine, Oncology, Ovarian cancer, Bevacizumab, and Clinical endpoint.
h-index
citations
664
works
14
NIH funding
primary concept
email

Recent publications

A genotype-first approach identifies high incidence of NF1 pathogenic variants with distinct disease associations
Nature Communications 2025cited by 13position: middledoi
Surgical and Blood-Based Minimal Residual Disease in Patients with Ovarian Cancer after First-line Therapy: Clinical Outcomes and Translational Opportunities
Clinical Cancer Research 2025cited by 7position: middledoi
Circulating tumor DNA monitoring in ovarian cancer patients receiving PARPi maintenance therapy: Can we further personalize treatment?
Gynecologic Oncology 2025cited by 4position: middledoi
Association of Tumor-informed Circulating Tumor DNA Detectability Before and After Radical Cystectomy with Disease-free Survival in Patients with Bladder Cancer
European Urology Oncology 2024cited by 31position: middledoi
Longitudinal Testing of Circulating Tumor DNA in Patients With Metastatic Renal Cell Carcinoma
JCO Precision Oncology 2024cited by 13position: middledoi
Niraparib and dostarlimab for the treatment of recurrent platinum-resistant ovarian cancer: results of a Phase II study (MOONSTONE/GOG-3032)
Gynecologic Oncology 2023cited by 25position: middledoi
DKK1 is a predictive biomarker for response to DKN-01: Results of a phase 2 basket study in women with recurrent endometrial carcinoma
Gynecologic Oncology 2023cited by 23position: middledoi
Circulating tumor DNA monitoring for early recurrence detection in epithelial ovarian cancer
Gynecologic Oncology 2022cited by 74position: middledoi
Molecular profiles of endometrial cancer tumors among Black patients
Gynecologic Oncology 2022cited by 28position: middledoi
Genomic profiling in low grade serous ovarian cancer: Identification of novel markers for disease diagnosis and therapy
Gynecologic Oncology 2022cited by 20position: firstdoi
MOONSTONE/GOG-3032: Interim analysis of a phase 2 study of niraparib + dostarlimab in patients (pts) with platinum-resistant ovarian cancer (PROC).
Journal of Clinical Oncology 2022cited by 10position: middledoi
Neratinib in patients with HER2-mutant, metastatic cervical cancer: Findings from the phase 2 SUMMIT basket trial
Gynecologic Oncology 2020cited by 70position: middledoi
NCCN Guidelines Insights: Ovarian Cancer, Version 1.2019
Journal of the National Comprehensive Cancer Network 2019cited by 329position: middledoi
Comparison of bevacizumab alone or with chemotherapy in recurrent ovarian cancer patients
Gynecologic Oncology 2015cited by 17position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Rebecca C. Arend · University of South Carolina3 papers (2022–2025)Linda Duska · University of Virginia3 papers (2022–2023)Bradley J. Monk · University of Cincinnati Medical Center3 papers (2020–2023)David M. O’Malley · Bexley Hall3 papers (2022–2023)Steven Waggoner · Case Western Reserve University2 papers (2022–2023)Sarah F. Adams · University of New Mexico2 papers (2022–2023)Roisin E. O’Cearbhaill · Maine Farmland Trust2 papers (2022–2023)Noelle Cloven · Texas Oncology2 papers (2022–2023)Leslie M. Randall · Inova Fairfax Hospital2 papers (2022–2023)Yasmine Baca · University of Kansas Medical Center2 papers (2022–2022)Panagiotis A. Konstantinopoulos · Harvard University2 papers (2022–2023)Jubilee Brown · Wake Forest University2 papers (2022–2022)Heather Dalton · Medical College of Wisconsin2 papers (2022–2023)Nathaniel Jones · USA Mitchell Cancer Institute2 papers (2022–2022)Hye Sook Chon · Moffitt Cancer Center2 papers (2022–2023)Marilyn Huang · University of Virginia2 papers (2022–2023) · 2 papers (2022–2023)Robert L. Coleman · MD Anderson Cancer Center Madrid2 papers (2022–2023)Minetta C. Liu · Signature Research (United States)2 papers (2024–2025)Stéphanie Gaillard · Johns Hopkins Medicine2 papers (2022–2023)